[{"data":1,"prerenderedAt":202},["ShallowReactive",2],{"$f2snw8zeffcxz6":3},{"schema":4,"slug":5,"series":6,"series_slug":7,"name":8,"year":9,"therapeutic_area":10,"generated_at":11,"counts":12,"top_targets":22,"top_modalities":55,"top_diseases":78,"top_companies":109,"key_results":131,"trends":187,"previous_editions":196,"comparison":169,"highlighted_classes":200},1,"esmo-gi-2026","ESMO GI","esmo-gi","ESMO GI Congress 2026",2026,"Oncology","2026-11-05T22:19:09Z",{"abstracts":13,"drug_linked":14,"companies":15,"by_phase":16},575,311,55,{"Phase 1":17,"Phase 1\u002F2":18,"Phase 2":19,"Phase 2\u002F3":20,"Phase 3":21},18,10,45,5,30,[23,27,30,34,38,42,45,48,50,53],{"name":24,"count":25,"share":26},"TS",61,20,{"name":28,"count":29,"share":17},"CD274",56,{"name":31,"count":32,"share":33},"PDCD1",36,12,{"name":35,"count":36,"share":37},"TOP1",27,9,{"name":39,"count":40,"share":41},"TUBB",21,7,{"name":43,"count":44,"share":20},"ERBB2",14,{"name":46,"count":33,"share":47},"TYMP",4,{"name":49,"count":33,"share":47},"VEGFR2",{"name":51,"count":18,"share":52},"EGFR",3,{"name":54,"count":18,"share":52},"VEGFA",[56,60,64,66,69,71,74,76],{"name":57,"count":58,"share":59},"Small molecules",178,57,{"name":61,"count":62,"share":63},"Monoclonal antibodies",147,47,{"name":65,"count":44,"share":20},"Antibody-drug conjugates",{"name":67,"count":41,"share":68},"Bispecific antibodies",2,{"name":70,"count":41,"share":68},"Peptides",{"name":72,"count":73,"share":68},"Natural-product mixtures and botanicals",6,{"name":75,"count":20,"share":68},"Radiopharmaceuticals",{"name":77,"count":47,"share":4},"Non-antibody therapeutic proteins",[79,83,86,88,91,95,98,100,103,106],{"name":80,"count":81,"share":82},"colorectal cancer (CRC)",70,23,{"name":84,"count":85,"share":44},"hepatocellular carcinoma (HCC)",44,{"name":87,"count":32,"share":33},"pancreatic adenocarcinoma (PDAC)",{"name":89,"count":90,"share":37},"gastric cancer (GC)",28,{"name":92,"count":93,"share":94},"gastroesophageal junction adenocarcinoma",25,8,{"name":96,"count":97,"share":41},"biliary cancer",22,{"name":99,"count":26,"share":73},"gastric adenocarcinoma",{"name":101,"count":102,"share":20},"metastatic colon cancer (mCRC)",17,{"name":104,"count":105,"share":20},"Esophageal Squamous Cell Carcinoma (ESCC)",16,{"name":107,"count":108,"share":20},"pancreatic cancer (PC)",15,[110,112,115,117,119,121,123,125,127,129],{"name":111,"count":32,"share":33},"Genentech",{"name":113,"count":114,"share":18},"AstraZeneca",31,{"name":116,"count":90,"share":37},"Bristol Myers Squibb",{"name":118,"count":105,"share":20},"Eli Lilly",{"name":120,"count":44,"share":20},"Taiho Pharmaceutical",{"name":122,"count":18,"share":52},"Pfizer",{"name":124,"count":18,"share":52},"Sanofi",{"name":126,"count":94,"share":52},"Roche",{"name":128,"count":41,"share":68},"Assertio",{"name":130,"count":41,"share":68},"Servier",[132,139,145,151,157,165,172,178],{"title":133,"drug":134,"company":113,"phase":136,"disease":84,"finding":137,"url":138},"Tumour response analyses by RECIST v1.1 and mRECIST in the phase III EMERALD-3 study of tremelimumab plus durvalumab with or without lenvatinib plus transarterial chemoembolisation (TACE) in embolisation-eligible hepatocellular carcinoma (eeHCC)",{"name":135,"slug":135},"tremelimumab","Phase 3","PFS per RECIST v1.1 by BICR showed a statistically significant improvement for STRIDE + L + TACE vs TACE (HR, 0.70 [95% CI, 0.57–0.86]; p=0.0007) at DCO1 (2 Sep 2025) and a clinically meaningful improvement for STRIDE + TACE vs TACE (0.71 [0.56–0.91]) at DCO2.","https:\u002F\u002Fcattendee.abstractsonline.com\u002Fmeeting\u002F21569\u002FPresentation\u002F1065",{"title":140,"drug":141,"company":116,"phase":136,"disease":80,"finding":143,"url":144},"Second-line adagrasib plus cetuximab vs chemotherapy in patients with KRASG12C-mutated metastatic colorectal cancer: Results from the KRYSTAL-10 trial",{"name":142,"slug":142},"adagrasib","Median PFS per BICR was 7.5 mo with Ada + Cetux vs 8.1 mo with chemo (HR 0.89 [95% CI 0.71–1.13]; P = 0.32).","https:\u002F\u002Fcattendee.abstractsonline.com\u002Fmeeting\u002F21569\u002FPresentation\u002F1066",{"title":146,"drug":147,"company":116,"phase":136,"disease":84,"finding":149,"url":150},"Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line (1L) treatment for unresectable hepatocellular carcinoma (uHCC): 4-year (yr) follow-up (FU) expanded analyses in the Chinese population of CheckMate 9DW",{"name":148,"slug":148},"nivolumab","Objective response rate was higher with NIVO + IPI (37%) vs LEN\u002FSOR (16%) and median duration of response was 39.4 and 7.2 mo in NIVO + IPI and LEN\u002FSOR arms, respectively.","https:\u002F\u002Fcattendee.abstractsonline.com\u002Fmeeting\u002F21569\u002FPresentation\u002F350",{"title":152,"drug":153,"company":113,"phase":136,"disease":99,"finding":155,"url":156},"Immune-mediated adverse events (imAEs) in MATTERHORN: A phase III study of durvalumab (D) plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric\u002Fgastroesophageal junction (G\u002FGEJ) adenocarcinoma",{"name":154,"slug":154},"durvalumab","EFS improved with D + FLOT in pts with (HR 0.62; 95% CI 0.40–0.91) and without imAEs (HR 0.70; 95% CI 0.53–0.90) vs P + FLOT.","https:\u002F\u002Fcattendee.abstractsonline.com\u002Fmeeting\u002F21569\u002FPresentation\u002F860",{"title":158,"drug":159,"company":161,"phase":162,"disease":87,"finding":163,"url":164},"Zolbetuximab plus gemcitabine and nab-paclitaxel (GN) in patients (pts) with claudin 18 isoform 2 (CLDN18.2)+ metastatic pancreatic adenocarcinoma (mPAC): phase II GLEAM study",{"name":160,"slug":160},"zolbetuximab","Astellas Pharma","Phase 2","Median OS was 13.7 vs 13.6 months with zolbetuximab + GN vs GN; HR, 1.00 (95% CI, 0.78–1.29); P = 0.499.","https:\u002F\u002Fcattendee.abstractsonline.com\u002Fmeeting\u002F21569\u002FPresentation\u002F156",{"title":166,"drug":167,"company":169,"phase":162,"disease":80,"finding":170,"url":171},"VIVA trial: Randomized comparison of adjuvant regorafenib plus durvalumab versus observation in stage IV colorectal cancer with no evidence of disease",{"name":168,"slug":168},"regorafenib",null,"Median OS was not reached in REGO-DURVA vs 43.6 months in OBS (HR 0.85; 95% CI: 0.29–2.44; p=0.76).","https:\u002F\u002Fcattendee.abstractsonline.com\u002Fmeeting\u002F21569\u002FPresentation\u002F206",{"title":173,"drug":174,"company":169,"phase":162,"disease":80,"finding":176,"url":177},"Cadonilimab plus bevacizumab and mFOLFOX6 as first-line treatment for advanced unresectable MSS, RAS-mutant metastatic colorectal cancer: Results from a multicenter, open-label, phase II study (BECOME3)",{"name":175,"slug":175},"cadonilimab","The ORR in BECOME3 reached 64.2% (including 5.7% complete responses), compared to 54.5% (0.8% CR) in the bevacizumab-chemotherapy group of BECOME.","https:\u002F\u002Fcattendee.abstractsonline.com\u002Fmeeting\u002F21569\u002FPresentation\u002F234",{"title":179,"drug":180,"company":183,"phase":184,"disease":87,"finding":185,"url":186},"First-in-human phase I\u002FIIa study of ulenistamab (PBP1510), an anti-PAUF monoclonal antibody, in metastatic pancreatic adenocarcinoma",{"name":181,"slug":181,"named_as":182},"ulenistamab","PBP1510","Prestige Biopharma","Phase 1\u002F2","In combination cohorts (N=18), 13 patients (72.2%) experienced PBP1510-related TRAEs, predominantly Grade 1–2 (66.7%); the most common (>15%) were anaemia, diarrhoea, and nausea.","https:\u002F\u002Fcattendee.abstractsonline.com\u002Fmeeting\u002F21569\u002FPresentation\u002F599",{"summary":188,"bullets":190},[189],"Small molecules were the most frequent modality (57% of drug-linked abstracts). TS was the most frequent target (20%). Colorectal cancer (CRC) was the most frequent disease (23%).",[191,192,193,194,195],"Genentech had the largest company share (12% of drug-linked abstracts).","Antibody-drug conjugates accounted for 5% of drug-linked abstracts.","Monoclonal antibodies were the next most frequent modality (47%).","CD274 was the next most frequent target (18%).","Hepatocellular carcinoma (HCC) was the next most frequent disease (14%).",[197],{"year":198,"abstracts":199},2025,360,[201],{"name":65,"count":44,"share":20,"previous_count":169,"previous_share":169,"direction":169},1793970603101]